Trial *
Publication Winchester S, J Infect, 2021 (published paper)
Funding: Private (SaNOtize Research & Development Corporation, Canada, through Metanoic Health Ltd., UK.)
Conflict of interest: *
| Methods | |
| RCT | |
| Location :
Single center / UK Follow-up duration (days): 18 | |
| Inclusion criteria | Adults (18–70 years) who were isolated with mild COVID-19 infection confirmed by laboratory SARS-CoV-2 RT-PCR nasal and throat swab within the 48 h of randomisation |
| Exclusion criteria | NR |
| Interventions | |
| Treatment
Nitric Oxide Nasal Spray 4 sprays (each 120–140μL of solution) nasally 5-6 times a day for 9 days. |
|
| Control
Placebo | |
| Participants | |
| Randomized 80 participants (n1=40 / n2= 40) | |
| Characteristics of participants N=80 Mean age : 44 29 males Severity : Mild: n=0 / Moderate: n=0/ Severe: n=0 Critical: n=0 | |
| Primary outcome | |
| In the register NR | |
| In the report NR | |
| Documents available |
Protocol NR Statistical plan NR Data-sharing stated
|
| Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
|
| General comment |